<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSourcesOutput xmlns:ns2="local"><Sources><Source id="618868" type="PR">Interim Financial Statements (Consolidated)for the six months ended September 30, 2004: Supplement</Source><Source id="545339" type="PR">Financial Statements(Consolidated)for the year ended March 31, 2004: Supplement</Source><Source id="553898" type="SERIAL">New Drugs in the R&amp;amp;D Pipeline</Source><Source id="279889" type="SERIAL">Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-Sulfonylamino acid derivatives</Source><Source id="619001" type="CORPORATE">Better human health is our commitment, improved performance is our goal</Source><Source id="512223" type="CORPORATE">Drugs under Development: Shionogi Drug Development Pipeline</Source><Source id="507953" type="CORPORATE">Annual Report 2003: Shionogi &amp;amp; Co</Source><Source id="491461" type="CORPORATE">Company Pipeline: May 2003</Source></Sources></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSourcesOutput>